"Medical and Surgical Diseases of the Retina and Vitreous"

During the past decade, Vitreo-Retinal Associates conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vitreo-Retinal Associates" #1 sponsor was "Applied Genetic Technologies Corp" with 3 trials, followed by "4D Molecular Therapeutics" with 2 trials sponsored, "IVERIC bio, Inc." with 2 trials sponsored, "Jaeb Center for Health Research" with 2 trials sponsored and "Kodiak Sciences Inc" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vitreo-Retinal Associates" #1 collaborator was "National Eye Institute (NEI)" with 3 trials as a collaborator, "Foundation Fighting Blindness" with 2 trials as a collaborator, "Janssen Research & Development, LLC" with 2 trials as a collaborator, "Centro Medico ABC" with 1 trials as a collaborator and "Duke University" with 1 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Vitreo-Retinal Associates" are "Achromatopsia" (3 trials), "X-Linked Retinitis Pigmentosa" (3 trials), "Eye Diseases" (2 trials), "Retinitis Pigmentosa" (2 trials) and "Autosomal Dominant Retinitis Pigmentosa" (1 trials). Many other conditions were trialed in "Vitreo-Retinal Associates" in a lesser frequency.

Most popular intervention types in "Vitreo-Retinal Associates" are "Drug" (9 trials), "Biological" (6 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (2 trials), "KSI-301" (2 trials), "Placebo" (2 trials), "Sham" (2 trials) and "Sham Procedure" (2 trials). Other intervention names were less common.

The vast majority of trials in "Vitreo-Retinal Associates" are 17 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Vitreo-Retinal Associates". 1 are not yet recruiting, 5 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Vitreo-Retinal Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Vitreo-Retinal Associates, 5 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".